PolyMedix Progresses With Drug That Mimics Body’s Natural Protective Proteins

Novel antibiotic brilacidin meets endpoints in Phase IIa study of 215 patients with acute bacterial skin and skin structure infection. Design went further than requirements in FDA guidance for ABSSSI.